Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Erlotinib May Result in Eyelash Trichomegaly, but Is Not a Marker for Treatment Efficacy: Presented at EMCTO By Jenny Powers LUGANO, Switzerland -- May 6, 2009 -- Erlotinib may result in eyelash trichomegaly after about 3 months of treatment in patients, according to a poster presented on May 3 here at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO) 2009. Skin rash is already considered to be a side effect of erlotinib related to clinical outcomes and a potential marker of response to treatment, but eyelash trichomegaly does not appear to be. Rinaldo Iacovelli, MD, Experimental Medicine Unit, Medical Oncology B Department, Sapienza University of Rome, Rome, Italy, and colleagues conducted a retrospective, observational analysis on reports of eyelash trichomegaly in patients being treated for non-small-cell lung cancer (NSCLC). They analysed reports from 160 patients with stage IV NSCLC who were treated with erlotinib 150 mg/day from January 2007 to December 2008 at the Sapienza University. In 5 patients (3.1%), eyelash growth was observed. Of these, 4 were female and nonsmokers, and 1 was a male smoker. The median age was 69.4 years (range, 54-78 years). All 5 patients reported an accelerated growth of bilateral tortuous eyelashes after a median time of 2.6 months (range, 2-4 months) of treatment; 3 patients complained of eye irritation, dry eye symptoms, and watering eyes; and 1 patient had an ophthalmological diagnosis of blepharitis. Of the 5 patients with eyelash trichomegaly, 3 also experienced cutaneous rash and diarrhoea; 2 experienced disease progression after 3 and 4 months of treatment (erlotinib was discontinued in these patients), and the other 3 reported stable disease for a median time of 13.3 months (range, 9-20 months). The authors stated that this side effect did not represent a marker for treatment efficacy, but does need to be further evaluated and documented as an adverse event. EMCTO 2009 was co-organised by the European Society for Medical Oncology (ESMO), the European Society for Therapeutic Radiology and Oncology (ESTRO), the European Society of Thoracic Surgeons (ESTS), and the European Respiratory Society (ERS). [Presentation title: Trichomegaly of the Eyelash Induced by Erlotinib Therapy. Abstract 141P] E-mail this page to a friend or colleague! To print, use this version